Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Heptares-Powered Sosei's Incoming CEO Explains What Happens Next

Executive Summary

Japanese company Sosei conducted a master stroke last year when it acquired UK biotechnology company Heptares as its in-house R&D engine. Deal after quality deal has ensued, and Sosei's share price has rocketed by more than 400%. Scrip's Sukaina Virji spoke to Sosei's COO – and CEO-elect – Peter Bains to find out what happens next.

Advertisement

Related Content

Sosei Names New CEO
Kymab, Heptares Enter GPCR Targeting Pact
Allergan 'Unusual Suspect' But Pipeline 'Hunger' A Perfect Match For Heptares
Pfizer Takes 3% Stake In Sosei On Back Of Heptares GPCR Deal
Teva Backs Small Molecule CGRP Approach To Migraine With Heptares Deal
AZ, Heptares In Possible $500m+ Oncology Deal
$400m Heptares acquisition to drive Sosei's R&D
GPCR-targeting antibodies focus for new deal

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC065053

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel